Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 2
2018 3
2019 1
2020 1
2021 2
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Radiotheranostic Agents in Hematological Malignancies.
Caers J, Duray E, Vrancken L, Marcion G, Bocuzzi V, De Veirman K, Krasniqi A, Lejeune M, Withofs N, Devoogdt N, Dumoulin M, Karlström AE, D'Huyvetter M. Caers J, et al. Among authors: krasniqi a. Front Immunol. 2022 Jul 5;13:911080. doi: 10.3389/fimmu.2022.911080. eCollection 2022. Front Immunol. 2022. PMID: 35865548 Free PMC article. Review.
Emerging applications of nanobodies in cancer therapy.
Awad RM, Meeus F, Ceuppens H, Ertveldt T, Hanssens H, Lecocq Q, Mateusiak L, Zeven K, Valenta H, De Groof TWM, De Vlaeminck Y, Krasniqi A, De Veirman K, Goyvaerts C, D'Huyvetter M, Hernot S, Devoogdt N, Breckpot K. Awad RM, et al. Among authors: krasniqi a. Int Rev Cell Mol Biol. 2022;369:143-199. doi: 10.1016/bs.ircmb.2022.03.010. Epub 2022 May 18. Int Rev Cell Mol Biol. 2022. PMID: 35777863
Targeted α-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment.
Ertveldt T, Krasniqi A, Ceuppens H, Puttemans J, Dekempeneer Y, Jonghe K, Mey W, Lecocq Q, Vlaeminck Y, Awad RM, Goyvaerts C, Veirman K, Morgenstern A, Bruchertseifer F, Keyaerts M, Devoogdt N, D'Huyvetter M, Breckpot K. Ertveldt T, et al. Among authors: krasniqi a. J Nucl Med. 2023 May;64(5):751-758. doi: 10.2967/jnumed.122.264752. Epub 2023 Apr 13. J Nucl Med. 2023. PMID: 37055223 Free article.
Stromal-targeting radioimmunotherapy mitigates the progression of therapy-resistant tumors.
Bolli E, D'Huyvetter M, Murgaski A, Berus D, Stangé G, Clappaert EJ, Arnouk S, Pombo Antunes AR, Krasniqi A, Lahoutte T, Gonçalves A, Vuylsteke M, Raes G, Devoogdt N, Movahedi K, Van Ginderachter JA. Bolli E, et al. Among authors: krasniqi a. J Control Release. 2019 Nov 28;314:1-11. doi: 10.1016/j.jconrel.2019.10.024. Epub 2019 Oct 15. J Control Release. 2019. PMID: 31626860
Identification of Nanobodies against the Acute Myeloid Leukemia Marker CD33.
Romão E, Krasniqi A, Maes L, Vandenbrande C, Sterckx YG, Stijlemans B, Vincke C, Devoogdt N, Muyldermans S. Romão E, et al. Among authors: krasniqi a. Int J Mol Sci. 2020 Jan 2;21(1):310. doi: 10.3390/ijms21010310. Int J Mol Sci. 2020. PMID: 31906437 Free PMC article.
Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model.
Ertveldt T, De Beck L, De Ridder K, Locy H, de Mey W, Goyvaerts C, Lecocq Q, Ceuppens H, De Vlaeminck Y, Awad RM, Keyaerts M, Devoogdt N, D'Huyvetter M, Breckpot K, Krasniqi A. Ertveldt T, et al. Among authors: krasniqi a. Mol Cancer Ther. 2022 Jul 5;21(7):1136-1148. doi: 10.1158/1535-7163.MCT-21-0791. Mol Cancer Ther. 2022. PMID: 35499391 Free PMC article.
15 results